A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors by Ahmad, AS et al.
A novel DNA methylation score accurately predicts death from prostate
cancer in men with low to intermediate clinical risk factors.
Ahmad, AS; Vasiljevi, N; Carter, P; Berney, DM; Møller, H; Foster, CS; Cuzick, J; Lorincz, AT
 
 
 
 
 
(c) 2016 The Author(s).
Licensed under a Creative Commons Attribution 3.0 License.
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/16201
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2016
A novel DNA methylation score accurately predicts death from 
prostate cancer in men with low to intermediate clinical risk 
factors
Supplementary Materials
Supplemetary Figure S1: Samples with missing DNA methylation (DNAme) measurements are shown by the gene 
name and DNAme. DPCa=death from prostate cancer.
Supplemetary Figure S2: Distribution of the DNA methylation (DNAme) score in the dataset. The vertical dashed lines are 
the 25th= 2.1, 50th =2.7, and 75th =3.2 centiles of the DNAme score. PCa=prostate cancer.
Supplemetary Figure S3: Predicted risk scores for the Gleason groups (Gleason<7 solid line, Gleason=7 dashed 
line, Gleason>7 dashed-dotted line) from a multivariate Cox model with Gleason + DNA methylation (DNAme) + 
Gleason*DNAme for each gene respectively. CCND2 and HSPB1 show statistically significant interaction with Gleason score, 
where patients with low Gleason become more at risk, when the DNAme of CCND2 and HSPB1 increases correspondingly.
Supplemetary Figure S4: Predicted risk scores from a multivariate Cox model with CCND2 + HSPB1+ 
CCND2*HSPB1+DPYS+MAL+PITx2+TIG1 as predictors. The DNA methylation (DNAme) of the interaction term was varied 
from 0 to 10000 and risk scores were computed for constant DNAme of the other genes. The lines with squares, circles, triangles point-up, 
diamonds, triangles point down and filled squares points present the predicted risk score for constant 0%, 10% 25%, 50% 75% and 100% 
DNAme of the other genes respectively.
Supplemetary Figure S5: The estimated Spearman’s rank correlation between all variables and scores.
Supplemetary Figure S6: Predicted probabilities Y= Stage-III of the missing stage values (n=240, death from prostate 
cancer (DPCa=67) in the sensitivity analysis using Gleason, PSA, Extent and Age at diagnostic. The solid and dashed lines 
show the cutoff values of 0.176 and 0.5 respectively. These cutoff values were used to classify patients to Stage I and II (less than cutoff 
value) and Stage-III (greater or equal to cutoff value). The cutoff value of 0.176 gave highest Youden's J statistic in the test data (data 
without missing Stage, n=333, DPCa=94) and the decision rule’s cutoff value of 0.5 (i.e. model correctly classified). Patients with missing 
clinical variables PSA and extent of disease, as well as invalid methylation measurements, were excluded from the statistical analysis 
(supplementary Figure S1). In addition, there were approximately 42% missing T-stage values. A categorical binary T-stage variable was 
recorded using 1 to indicate T3 samples and 0 for T1 or T2 samples. The missing T-stage values were imputed with the most frequent 
observed T1-T2 stage (47%) value.
Supplementary Table S1: Median, interquartile range (IQR) and number of missing values of each 
marker
marker median (IQR: Q25-Q75%) N missing values
Age 70.5 (6.3: 66.98–73.31) 0
PSA 8 (19.5: 2.5–22) 19
Extent (%) 16.7 (48.2: 4.85–53.0) 3
CCND2 30.1 (30.9: 14.70–45.60) 10
DPYS 35.6 (48.119: 10.96–59.08) 59
HSPB1 6.2 (16.81: 2.94–19.75) 35
MAL 21.3 (28.68: 9.92–38.60) 34
PITX2 18.6 (24.375: 8.1–32.48) 65
TIG1 5.3 (22.82: 2–24.817) 30
Supplementary Table S2: A sensitivity analysis of parameterwise shrinkage factors for the 
regression coefficients of the multivariate Cox model was performed by the Jackknife (i.e. leave-
one-out resampling) method, considering methylation of the six genes and an interaction between 
CCND2 and HSPB1
Univariate Bivariate
HR (95% CI) LRTa p HR (95% CI) LRTa p
AltM 3.14 (2.06, 4.76) 30.58 3.20e–8 2.16 (1.39, 3.34) 11.87 0.001
CAPRA 4.21 (2.54, 6.99) 31.05 2.50e–8 1.43 (1.18, 1.72) 13.82 0.000
χ² (d.f., p) 44.26 (2, 2.45e–10)
c-index (se) 0.733 (0.04)
An alternative methylation score (AltM) was developed using the shrunken regression coefficients: AltM score= 
0.026*log(1+CCND2)+0.112*log(1+HSPB1)-0.041*log(1+CCND2*HSPB1)+ 0.229*log(1+DPYS)-0.020*log(1+MAL)+0.
088*log(1+PITX2)+0.378*log(1+TIG1).
a likelihood ratio chi-square test.
Supplementary Table S3: In a sensitivity analysis, the missing T-stage values were predicted by fitting a 
multivariate logistic regression with Gleason, PSA, log(1+Extent), age at diagnosis as predictors, and T-stage as the 
response variable with T1&T2 (n=270, 81%), and T3 (n=63, 19%) in the 333 patients with data available for all 
clinical and methylation variables
T-stage cut-off = 0.176 T-stage cut-off = 0.5
n = 375, DPCa = 55 n = 385, DPCa = 57
HR (95% CI) LRTa p HR (95% CI) LRTa P
DNAme 2.02 (1.41, 2.89) 14.77 0.0001 2.0 (1.37, 2.91) 12.87 0.0003
CAPRA 1.42 (1.17, 1.72) 12.89 0.0003 1.33 (1.12, 1.59) 10.39 0.001
χ² (d.f., p) 48.99 (2, 2.3e–11) 44.75 (2, 1.9e–10)
c-index (se) 0.744 (0.041 ) 0.738 (0.040)
All predictors were significant (p <0.05). The model likelihood ratio test was 80.72 (d.f.=4, p < 0.0001). AUC of the fitted 
multivariate logistic regression was 0.84 (95% CI: 0.78-0.89), which shows good utility in predicting the responses of 
individual subjects with Youden’s index providing a sensitivity of 84% and specificity of 73%. The missing T-stage values of 
240 men were imputed using predicted probabilities from this fitted logistic regression model choosing a cutoff value of 0.5 
to best match the observed T-stage distribution. The resulting imputed T-stage values fell into the following groups: T1&T2 
N = 224 (90%) and T3 N = 16 (10%). Bivariate analysis for death from prostate cancer in the sensitivity analysis with two 
cutoff values used for dichotomizing the predicted T-stage values. DNAme=DNA methylation.
a likelihood ratio chi-square.
Supplementary Table S4: Competing risks regression (Fine-Gray model) analysis of death from 
prostate cancer, Alive=140, DPCa = 57, and DOC=188
univariate bivariate
HR (95% CI) PLRTa HR (95% CI) PLRTa p
DNAme 2.56 (1.79, 3.66) 30.6 2.00 (1.41, 2.82) 15.36 8.90e-5
CAPRA 1.56 (1.32, 1.84) 26.1 1.36 (1.15, 1.61) 12.95 3.20e-4
pseudo LR test 41.1
a Pseudo likelihood ratio chi-square test. DNAme = methylation score.
